Advertisement

Treatment Sequencing for Resectable Disease

  • Mariana I. Chavez
Chapter

Abstract

The management of resectable or localized pancreatic cancer (PC) remains controversial. Although randomized controlled trials have demonstrated a benefit in survival associated with adjuvant therapy for PC, most of these patients do not receive postoperative chemotherapeutic treatment due to the high rate of complications associated with pancreatic surgery. Recognizing that surgery may be necessary but usually not sufficient for cure, there has been growing interest in neoadjuvant treatment sequencing, which benefits patients with both localized and micrometastatic PC by ensuring the delivery of systemic therapies. For patients with truly localized disease, neoadjuvant therapy ensures the delivery of all components of the multimodality treatment. For patients who have clinically occult metastatic disease, neoadjuvant therapy allows for the early delivery of systemic therapy and avoids the morbidity and mortality of a surgical resection which would provide no oncologic benefit. This chapter details the rationale of treatment sequencing for resectable PC and provides specific recommendations for staging and treatment sequencing for patients with resectable pancreatic disease.

Keywords

Pancreas Adenocarcinoma Resectable Localized Neoadjuvant Chemotherapy Chemoradiation 

References

  1. 1.
    Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.CrossRefGoogle Scholar
  2. 2.
    Stat Fact Sheet: Pancreas Cancer [10/30/2013]. Available online: http://seer.cancer.gov/statfacts/html/pancreas.html.
  3. 3.
    Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–75.CrossRefGoogle Scholar
  4. 4.
    Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.CrossRefGoogle Scholar
  5. 5.
    Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.CrossRefGoogle Scholar
  6. 6.
    Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147:753–60.CrossRefGoogle Scholar
  7. 7.
    Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Cancer Netw. 2010;8:972–1017.CrossRefGoogle Scholar
  8. 8.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefGoogle Scholar
  9. 9.
    Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024.Google Scholar
  10. 10.
    Mayo SC, Gilson MM, Herman JM, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214:33–45.CrossRefGoogle Scholar
  11. 11.
    Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21:2873–81.CrossRefGoogle Scholar
  12. 12.
    Evans DB, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.CrossRefGoogle Scholar
  13. 13.
    Takahashi H, Ogawa H, Ohigashi H, et al. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011;150:547–56.CrossRefGoogle Scholar
  14. 14.
    Raut CP, Evans DB, Crane CH, et al. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am. 2004;13:639–61, ix.CrossRefGoogle Scholar
  15. 15.
    Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993;217:144–8.CrossRefGoogle Scholar
  16. 16.
    Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980;46:1945–9.CrossRefGoogle Scholar
  17. 17.
    Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.CrossRefGoogle Scholar
  18. 18.
    Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487–95.CrossRefGoogle Scholar
  19. 19.
    Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–74.CrossRefGoogle Scholar
  20. 20.
    Cooper AB, Parmar AD, Riall TS, et al. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg. 2015;19:80–6; discussion 86–7.CrossRefGoogle Scholar
  21. 21.
    Takahashi H, Ohigashi H, Gotoh K, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258:1040–50.CrossRefGoogle Scholar
  22. 22.
    Christians KK, Heimler JW, George B, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159:893–900.CrossRefGoogle Scholar
  23. 23.
    Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2016;35:515–22.CrossRefGoogle Scholar
  24. 24.
    Sharma G, Whang EE, Ruan D, et al. Efficacy of neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma: a decision analysis. Ann Surg Oncol. 2015;22:S1229–37.CrossRefGoogle Scholar
  25. 25.
    de Geus SWL, Eskander MF, Tseng JF, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: a nationwide propensity score matched analysis. Surgery. 2016;161:592–601.CrossRefGoogle Scholar
  26. 26.
    Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery vs surgery alone in resectable pancreatic cancer:a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–12.CrossRefGoogle Scholar
  27. 27.
    Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16.CrossRefGoogle Scholar
  28. 28.
    Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol. 2017;9(12):457–65.CrossRefGoogle Scholar
  29. 29.
    ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifiers NCT01314027, NCT02047513, NCT02172976, NCT01660711 and NCT01726582. Available from: https://clinicaltrials.gov/
  30. 30.
    Katz MH, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17:505.CrossRefGoogle Scholar
  31. 31.
    Von Hoff DD, Goldstein D, Renschler MF. Albumin- bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med. 2014;370:479–80.Google Scholar
  32. 32.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefGoogle Scholar
  33. 33.
    Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20(10):2537–44.CrossRefGoogle Scholar
  34. 34.
    Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14(7):2088–96. Epub 2007 Apr 24.CrossRefGoogle Scholar
  35. 35.
    Heinrich S, Pestalozzi BC, Schäfer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526–31.CrossRefGoogle Scholar
  36. 36.
    OʼReilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142–8.CrossRefGoogle Scholar
  37. 37.
    Van Tienhoven G, Versteijne E, Suker M, Groothuis KBX, Busch OR, Bonsing BA. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018;36(18_suppl)  https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4002.CrossRefGoogle Scholar
  38. 38.
    Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux J-L, Juzyna B, Gourgou S, O’Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet J-B. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. New Eng J Med. 2018;379(25):2395–406.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mariana I. Chavez
    • 1
  1. 1.Department of General SurgeryThe Surgical ClinicNashvilleUSA

Personalised recommendations